Sutro announces data from Phase 1b study of Luvelta in combo with Bevacizumab

Sutro Biopharma announced updated data from the ongoing Phase 1b study of luveltamab tazevibulin in combination with bevacizumab for patients with epithelial ovarian cancer in a poster presentation at the 2024 European Society For Medical Oncology Congress in Barcelona, Spain. In this study, luvelta plus bevacizumab has demonstrated encouraging antitumor activity in patients with late-stage ovarian cancer irrespective of Folate Receptor-alpha expression, including patients with no FRalpha expression, and prior bevacizumab treatment, with an overall response rate of 35%. These early data in combination may offer a non-biomarker driven approach to treat patients with EOC. The expansion phase of the study is ongoing at the recommended phase 2 dose of luvelta in combination with bevacizumab with an additional 23 patients enrolled to date; initial data is expected in the first half of 2025. 18 patients were enrolled; one patient remains on treatment. Luvelta plus bevacizumab demonstrated encouraging antitumor activity in 17 RECIST evaluable patients: At the RP2D, an Objective Response Rate of 56% was observed; no patients had a response at 3.5 mg/kg and 50% of patients had a response at 5.2 mg/kg. An ORR of 35% was observed in the overall population with a median duration of response of 9.3 months. In patients with greater than or equal to 25% FRalpha expression, an ORR of 44% was observed; in patients with less than25% FRalpha expression, an ORR of 29% was observed. No new safety signals were observed compared with either agent alone; consistent with previous reported luvelta safety results, the most common adverse event was neutropenia.